☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
IgA Nephropathy
CSL Vifor and Travere Therapeutics’ FILSPARI (sparsentan) Received European Commission Approval Against IgA Nephropathy
April 24, 2024
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)
April 16, 2024
Vertex to Acquire Alpine Immune Sciences for ~$4.9B
April 11, 2024
Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)
March 12, 2024
CSL Vifor and Travere Therapeutics’ Filspari (sparsentan) Gains CHMP’s Positive Opinion to Treat IgA Nephropathy
February 23, 2024
Novartis Reports Acquisition of SanReno Therapeutics to Advance Transformative Medicines for Kidney Disease
January 8, 2024
Load more...
Back to Home